Therapeutic drug monitoring · 2026
Influence of Genetic Polymorphisms on Tacrolimus Pharmacokinetics in Whole Blood, Plasma, and Peripheral Blood Mononuclear Cells in Chinese Kidney Allograft Recipients.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lu Yun-Zhu, Lu Xiao-Ling, Wang Yu-Ping, Lu Jia-Qian, Shao Kun, An Hui-Min, Shi Hao-Qiang, Zhou Pei-Jun, Chen Bing
Аннотация
BACKGROUND: Significant variations in tacrolimus (TAC) pharmacokinetics (PK) occur across whole blood, plasma, and peripheral blood mononuclear cells (PBMCs). In the present study, TAC plasma levels were estimated based on TAC whole blood levels, and the influence of genetic polymorphisms on the PKs of TAC were compared between whole blood, plasma, and PBMCs.
METHODS: Whole blood, plasma, and PBMC samples of 36 kidney allograft recipients were collected at 0-12 hours after the morning dose after 1 month of therapy. TAC levels in whole blood (C wb ), plasma (C p ), and PBMCs were determined using liquid chromatography-tandem mass spectrometry. TAC C p was estimated based on C wb and hematocrit. PK parameters of TAC in whole blood, plasma, and PBMC were estimated. The influence of CYP3A5 and ABCB1 genotypes on TAC exposure was evaluated.
RESULTS: TAC whole blood trough concentration (C 0 ), maximum concentration (C max ), and area under the concentration-time curve (AUC 0-12 ) were 8.60 ± 5.59 ng/mL, 20.1 ± 7.69 ng/mL, and 144 ± 69.4 ng⋅h/mL, respectively; 0.21 ± 0.12 ng/mL, 0.51 ± 0.35 ng/mL, and 3.02 ± 1.68 ng⋅h/mL, respectively, in plasma; and 0.026 ± 0.017 ng/10 6 PBMCs, 0.078 ± 0.047 ng/10 6 PBMCs, 0.49 ± 0.30 ng⋅h/10 6 PBMCs, respectively. A moderate correlation was observed between C 0 , C max , and AUC 0-12 in plasma and PBMCs ( P < 0.05). Recipients with CYP3A5*3/*3 genotype exhibited a higher AUC 0-12 in PBMC than those with the *1/*1 or *1/*3 genotypes ( P < 0.05). Recipients with ABCB1 3435 TT genotype showed higher C 0 , C max , and AUC 0-12 values in PBMC than those with the 3435CC or CT genotypes ( P < 0.01).
CONCLUSIONS: Plasma TAC concentrations in Chinese kidney allograft recipients can be estimated using whole blood TAC and hematocrit levels. Genetic polymorphisms of CYP3A5*3 and ABCB1 (3435C > T) significantly influenced TAC exposure in both plasma and PBMC.
METHODS: Whole blood, plasma, and PBMC samples of 36 kidney allograft recipients were collected at 0-12 hours after the morning dose after 1 month of therapy. TAC levels in whole blood (C wb ), plasma (C p ), and PBMCs were determined using liquid chromatography-tandem mass spectrometry. TAC C p was estimated based on C wb and hematocrit. PK parameters of TAC in whole blood, plasma, and PBMC were estimated. The influence of CYP3A5 and ABCB1 genotypes on TAC exposure was evaluated.
RESULTS: TAC whole blood trough concentration (C 0 ), maximum concentration (C max ), and area under the concentration-time curve (AUC 0-12 ) were 8.60 ± 5.59 ng/mL, 20.1 ± 7.69 ng/mL, and 144 ± 69.4 ng⋅h/mL, respectively; 0.21 ± 0.12 ng/mL, 0.51 ± 0.35 ng/mL, and 3.02 ± 1.68 ng⋅h/mL, respectively, in plasma; and 0.026 ± 0.017 ng/10 6 PBMCs, 0.078 ± 0.047 ng/10 6 PBMCs, 0.49 ± 0.30 ng⋅h/10 6 PBMCs, respectively. A moderate correlation was observed between C 0 , C max , and AUC 0-12 in plasma and PBMCs ( P < 0.05). Recipients with CYP3A5*3/*3 genotype exhibited a higher AUC 0-12 in PBMC than those with the *1/*1 or *1/*3 genotypes ( P < 0.05). Recipients with ABCB1 3435 TT genotype showed higher C 0 , C max , and AUC 0-12 values in PBMC than those with the 3435CC or CT genotypes ( P < 0.01).
CONCLUSIONS: Plasma TAC concentrations in Chinese kidney allograft recipients can be estimated using whole blood TAC and hematocrit levels. Genetic polymorphisms of CYP3A5*3 and ABCB1 (3435C > T) significantly influenced TAC exposure in both plasma and PBMC.